Charles River Laboratories | CRL - Equity Capital And Reserves


Charles River Laboratories reported $3.16B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agilent USD 6.91B 167M Dec/2025
Align Technology USD 3.96B 44.68M Sep/2025
Bio-Rad Laboratories USD 7.45B 716.8M Dec/2025
Bruker USD 2.49B 625.6M Sep/2025
Cardinal Health USD -2.88B 5M Dec/2025
Charles River Laboratories USD 3.16B 240.82M Dec/2025
Cigna USD 41.71B 92M Dec/2025
Concord Medical Services Hldg CNY -1.88B 12.91M Jun/2023
CVS Health USD 75.21B 2.29B Dec/2025
Danaher USD 52.53B 1.46B Dec/2025
Dentsply International USD 1.48B 482M Sep/2025
Elevance Health USD 44.03B 73M Dec/2025
Galapagos EUR 2.45B 196.86M Sep/2025
Hologic USD 5.25B 197.2M Dec/2025
Humana USD 17.66B 865M Dec/2025
Illumina USD 2.72B 342M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
IQVIA Holdings USD 6.5B 343M Dec/2025
Laboratory Of America USD 8.62B 93.2M Dec/2025
Lonza CHF 9.33B 23M Dec/2024
McKesson USD -1.3B 441M Dec/2025
Merck EUR 28.94B 677M Sep/2025
Mettler Toledo International USD -23.64M 225.56M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Quest Diagnostics USD 7.17B 88M Dec/2025
Revvity USD 7.38B 180.27M Sep/2025
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
UnitedHealth USD 105.81B 1.03B Sep/2025
Veradigm USD 1.18B 19.32M Sep/2022
Waters USD 2.56B 230.55M Dec/2025
West Pharmaceutical Services USD 3.18B 124.5M Dec/2025